0 CHECKOUT

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

  • ID: 3229986
  • April 2015
  • Region: Global
  • 103 Pages
  • Transparency Market Research
Peptide Therapeutics Market Expected to Reach USD 23.7 Billion Globally in 2020

FEATURED COMPANIES

  • Amgen, Inc.
  • Bachem Holding AG
  • Ipsen S.A.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Roche Holdings AG
  • MORE

The global peptide therapeutics market report provides detailed analysis, market size, and forecast for therapeutic peptides approved for various indications. The market is studied from four major perspectives: applications, route of administration, marketing status, and geography. Application segments of the global peptide therapeutics market have been further sub-segmented by major branded peptide drugs approved by regulatory authorities across the globe. Various applications considered in the report include metabolic disorders, hematological disorders, cancer, cardiovascular disorders, central nervous system disorders, infection, gastrointestinal disorders, respiratory disorders, acromegaly, and others. Market size and forecast for leading drugs such as Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza, and Zoladex has been included along with in-depth market analysis. Segmentation by marketing status explains the impact of generic drugs on the overall peptide therapeutics market. Further, market segmentation of peptide drugs by route of administration provides quantitative insights into the growing demand for convenient methods for peptide drug administration. Details on READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen, Inc.
  • Bachem Holding AG
  • Ipsen S.A.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Roche Holdings AG
  • MORE

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations
1.5 Assumptions and Stipulations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview
3.1 Introduction
3.2 Emerging Trends in Peptide Therapeutics Market
3.2.1 Trends in Peptide Manufacturing Technology
3.2.2 Trends in Peptide API Supply
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides
3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth
3.3.1.3 Technological advancements have reduced total production cost of peptides
3.3.2 Restraints
3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers
3.3.2.2 Lack of regulatory standards
3.3.3 Opportunities
3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period
3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth
3.4 Regulatory Scenario
3.5 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyer
3.5.3 Threat of Substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Event Impact Analysis
3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
3.8 Market Share Analysis

Chapter 4 Global Peptide Therapeutics Market, by Applications
4.1 Introduction
4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
4.2 Cancer
4.2.1 Global Cancer Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.2.2 Zoladex (goserelin)
4.2.3 Velcade (bortezomib)
4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)
4.2.5 Others
4.3 Cardiovascular
4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.3.2 Angiomax (bivalirudin)
4.3.3 Integrilin (eptifibatide)
4.4 Central Nervous System
4.4.1 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.4.2 Copaxone (glatiramer)
4.5 Metabolic Disorders
4.5.1 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.5.2 Victoza (liraglutide)
4.5.3 Byetta (exenatide)
4.5.4 Others
4.6 Infection
4.6.1 Global Infection Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.6.2 Incivek (telaprevir)
4.6.3 Victrelis (boceprevir)
4.7 Hematological Disorders
4.7.1 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.7.2 Firazyr (icatibant)
4.7.3 Kalbitor (ecallantide)
4.8 Gastrointestinal Disorders
4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.8.2 Gattex (teduglutide)
4.8.3 Linzess (linaclotide)
4.9 Respiratory Disorders
4.9.1 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
4.10 Acromegaly
4.10.1 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.11 Other Applications
4.11.1 Global Other Applications Peptide Therapeutics market Revenue, 2012 - 2020 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
5.2 Parenteral Route of Administration
5.2.1 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
5.3 Oral Route of Administration
5.3.1 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status
6.1 Introduction
6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
6.2 Branded Peptide Therapeutics
6.2.1 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
6.3 Generic Peptide Therapeutics
6.3.1 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview
7.1 Introduction
7.1.1 Global Peptide Therapeutics Pipeline Overview

Chapter 8 Global Peptide Therapeutics Market, by Geography
8.1 Introduction
8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
8.2 North America
8.2.1 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
8.3 Europe
8.3.1 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
8.5 Rest of the World
8.5.1 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)

Chapter 9 Recommendations
9.1 Rigorous research and development (R&D) would yield new products
9.2 Facility expansion in emerging economies
9.3 Rapid inorganic growth through acquisitions

Chapter 10 Company Profiles
10.1 Amgen, Inc.
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.1.5 Recent Developments
10.2 AstraZeneca plc
10.2.1 Company Overview
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.2.5 Recent Developments
10.3 Bachem Holding AG
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.3.5 Recent Developments
10.4 CordenPharma International GmbH
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.4.5 Recent Developments
10.5 Eli Lilly and Company
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.5.5 Recent Developments
10.6 Ipsen S.A.
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.6.5 Recent Developments
10.7 Lonza Group Ltd.
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.7.5 Recent Developments
10.8 Merck & Co., Inc.
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.8.5 Recent Developments
10.9 Novartis AG
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.9.5 Recent Developments
10.10 Novo Nordisk A/S
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.10.5 Recent Developments
10.11 PolyPeptide Group
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.11.5 Recent Developments
10.12 Roche Holdings AG
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.12.5 Recent Developments
10.13 Sanofi
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.13.5 Recent Developments
10.14 Takeda Pharmaceutical Company Limited
10.14.1 Company Overview
10.14.2 Financial Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.14.5 Recent Developments
10.15 Teva Pharmaceutical Industries Ltd.
10.15.1 Company Overview
10.15.2 Financial Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.15.5 Recent Developments

List of Figures:
Fig. 1 Peptide Therapeutics Market Segmentation
Fig. 2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
Fig. 3 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
Fig. 4
Fig. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
Fig. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2013 (Value %)
Fig. 7 Global Central Nervous System Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Fig. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Fig. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Fig. 10 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
Fig. 11 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)
Fig. 12 Global Branded Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Fig. 13 Global Generic Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Fig. 14 North America Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Fig. 15 Europe Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Fig. 16 Asia Pacific Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Fig. 17 Rest of the World Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Fig. 18 Amgen, Inc: Annual Revenue, 2011 – 2013 (USD Million)
Fig. 19 AstraZeneca plc: Annual Revenue, 2011 – 2013 (USD Million)
Fig. 20 Bachem Holding AG: Annual Revenue, 2011 – 2013 (USD Million)
Fig. 21 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)
Fig. 22 Ipsen S.A.: Annual Revenue, 2011 – 2013 (USD Million)
Fig. 23 Lonza Group Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
Fig. 24 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
Fig. 25 Novartis AG Annual Revenue: 2011 – 2013 (USD Million)
Fig. 26 Novo Nordisk A/S Annual Revenue: 2011 – 2013 (USD Million)
Fig. 27 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million)
Fig. 28 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
Fig. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)
Fig. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)

List of Tables:
Table 1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
Table 2 Event Impact Analysis: Global Peptide Therapeutics Market
Table 3 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
Table 4 Global Cancer Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Table 5 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Table 6 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Table 7 Global Infection Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Table 8 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Table 9 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Table 10 Global Acromegaly Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Table 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
Table 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
Table 13 Global Peptide Therapeutics Market Pipeline Overview
Table 14 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen, Inc.
  • Bachem Holding AG
  • Ipsen S.A.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Roche Holdings AG
  • MORE

Therapeutic peptides are defined as short amino acid chains that have potential in managing disease symptoms, and in some cases cure them. The industry defines peptides as molecules shorter than 100 amino acids; while longer amino acid chains can be monoclonal antibodies and proteins. Insulin was the first peptide to be isolated and administered therapeutically, and is still the most commonly prescribed peptide, having been used for over half a century. Peptides have been explored for the treatment of various conditions such as cancer, cardiovascular disorders, respiratory disorders, blood disorders, central nervous system disorders and various others.

The peptide therapeutics market has developed at a significant pace in the recent past, leading to unparalleled growth in the number of regulatory approvals received in 2012. Thus, the increase in number of approved peptide-based drug products and expanding range of medical indications projects the increasing maturity of peptides as a class of pharmaceutical actives. Therapeutic peptides are approved for various application areas such as cancer, cardiovascular, central nervous system, gastrointestinal, infection, metabolic, pain, and respiratory. Cancer was estimated to be the largest application segment of the peptide therapeutics market in 2013; while the respiratory segment is expected to grow at the highest CAGR, due to the recent approval of Surfaxin (lucinactant). Major drugs driving growth of the overall peptide therapeutics market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex. As these drugs lose their patent exclusivity in the near future, the market for generic peptide drugs would flourish. However, difficulty in synthesis of complex peptides has restricted growth of the generic peptide drugs market.

Patent expiry has been the prime factor impeding market growth; while at the same time has also allowed deeper market penetration in low and middle income countries. The market is also restrained due to unavailability of convenient routes of drug administration, and lower drug stability at room temperature. Scientists, however, are trying to overcome these drawbacks through consistent research and development. With an escalating number of peptide therapeutic drug approvals and consistent launch of generics, the demand for peptide APIs is expected to rise in the near future. Hence, API manufacturers are trying to optimize economies of scale to reduce costs and also meet the rising peptide API demand. Thus, the supply side of the peptide therapeutics value chain would decide the fate of the global market.

The global peptide therapeutics market is largely concentrated in the western countries of North America and Europe, which account for more than 60% of the market share. Although these regions are currently the largest market segments, the compounded annual growth rate of the market in these regions is expected to be slower as compared to Asia Pacific. India, China and Japan are major countries driving the peptide therapeutics market in the Asia Pacific region. Japan is the second-largest individual pharmaceutical market, while India and China have large patient population due to high disease prevalence. Rapidly developing economy and increasing awareness about various disease treatments are other factors driving the market. India and China have emerged as major peptide API suppliers globally.

Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group. Peptisyntha Inc and Lonza Inc.

Note: Product cover images may vary from those shown

- Amgen, Inc.
- AstraZeneca plc
- Bachem Holding AG
- CordenPharma International GmbH
- Eli Lilly and Company
- Ipsen S.A.
- Lonza Group Ltd.
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- PolyPeptide Group
- Roche Holdings AG
- Sanofi
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S